Related Experiment Video
Updated: Feb 18, 2026
06:15
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
1.9K
Infantile hemangiomas with conjunctival involvement: An underreported occurrence
Martin Theiler1,2, Eulalia Baselga3, Christina Gerth-Kahlert4
1Department of Pediatric Dermatology, University Children's Hospital Zurich, Zurich, Switzerland.
Pediatric Dermatology
|November 17, 2017
Summary
Conjunctival infantile hemangiomas (IHs) present similarly to skin IHs and respond well to beta-blocker treatments. While uncommon, ocular complications can occur in some cases of conjunctival IH.
Area of Science:
- Pediatric Dermatology
- Ophthalmology
Background:
- Infantile hemangiomas (IHs) of the conjunctiva are rare, with limited information on their clinical course.
- This study addresses the lack of data on conjunctival IH presentation, complications, and treatment outcomes.
Purpose of the Study:
- To delineate the clinical presentation, complications, and treatment response of conjunctival infantile hemangiomas.
- To propose a classification for conjunctival IH.
Main Methods:
- Retrospective analysis of medical charts from three pediatric dermatology institutions.
- Inclusion of 22 individuals with conjunctival IH, collecting data on clinical characteristics, ophthalmologic findings, treatments, and outcomes.
Main Results:
- Conjunctival IH growth mirrored cutaneous IH.
- Ophthalmologic abnormalities occurred in 27% of cases, with 13.6% being severe.
- Seventy-seven percent of subjects required treatment, primarily due to ocular compromise risk.
- All treated individuals showed positive responses to topical timolol or systemic propranolol.
Conclusions:
- Conjunctival IH share clinical features with cutaneous IH.
- Beta-blocker therapy (timolol, propranolol) is effective for conjunctival IH.
- A minority of patients may experience ocular complications.
